Mehanizam djelovanja i terapija botulinum toksinom

Alajbegović, Azra; Alajbegović, Salem; HalimaResić
January 2008
Medical Archives / Medicinski Arhiv;2008, p53
Academic Journal
Botulinum neurotoxin (BoNT) is produced by Clostridium botulinum as a complex of proteins containing the neurotoxin itself and other nontoxic proteins. Activation of the neurotoxin occurs upon proteolytic cleavage into the heavy and light chains. This di-chain moiety is essential for neurotoxin and each chain is playing a unique role; the heavy chain mediates neurospecifics cell binding and entry, whereas the light chain, a protease, catalyzes the cleavage and inactivation of neuronal proteins that mediate neurotransmitter release. There are seven BoNT serotypes (A,B,CI,D,E,F, and G),all of which inhibit acetylcholine release, though their intracellular target proteins, the characteristics of their actions, and their potencies vary substantially. BoNT type A has been the most widely studied and applied serotype for therapeutic purposes. It has been a mainstay in the treatment of cervical dystonia, blepharospasm, and hemifacial spasm for years. BoNT has more recently emerged as an increasingly important therapeutic option in the clinical management of a broad array of conditions,including other focal dystonias, spasticity, cerebral palsy, equinovarus, gastrointestinal (GI) and urogenital disorders, hypersecretory disorders, facial lines due to hyperfunctional facial muscles .and recently, musculoskeletal pain disorders and headache.


Related Articles

  • Mehanizam djelovanja i terapija botulinum toksinom. Alajbegović, Azra; Alajbegović, Salem; HalimaResić // Medicinski Arhiv;2008, Vol. 62 Issue 1, p53 

    Botulinum neurotoxin (BoNT) is produced by Clostridium botulinum as a complex of proteins containing the neurotoxin itself and other nontoxic proteins. Activation of the neurotoxin occurs upon proteolytic cleavage into the heavy and light chains. This di-chain moiety is essential for neurotoxin...

  • Botulinum Toxin B: A Review of its Therapeutic Potential in the Management of Cervical Dystonia. Figgitt, D.P.; Noble, S. // Drugs;2002, Vol. 62 Issue 4, p705 

    Botulinum toxins are well known as the causative agents of human botulism food poisoning. However, in the past two decades they have become an important therapeutic mainstay in the treatment of dystonias including cervical dystonia, a neurological disorder characterised by involuntary...

  • AAN Updates Guidelines on the Uses of Botulinum Neurotoxin. WILKES, JENNIFER // American Family Physician;2/1/2017, Vol. 95 Issue 3, p198 

    The article discusses the guidelines published by the American Academy of Neurology (AAN) in 2008 on the use of botulinum neurotoxin. Topics covered include updates and recommendations as of February 2017 on four indications, such as blepharospasm, cervical dystonia, spasticity in adults, and...

  • POSTERIOR CRICOARYTENOID MYOPLASTY WITH MEDIALIZATION THYROPLASTY IN THE MANAGEMENT OF REFRACTORY ABDUCTOR SPASMODIC DYSPHONIA. Shaw, Gary Y.; Sechtem, Phillip R.; Rideout, Benji // Annals of Otology, Rhinology & Laryngology;Apr2003, Vol. 112 Issue 4, p303 

    Of the approximately 100,000 Americans with primary (idiopathic) laryngeal dystonia, 10% to 15% are thought to have the abductor form. Botulinum A toxin injected into the posterior cricoarytenoid muscle and/or cricothyroid muscle has been employed as the "gold standard" for therapeutic...

  • Botulinum toxin. Lees, A.J. // BMJ: British Medical Journal (International Edition);11/14/92, Vol. 305 Issue 6863, p1169 

    Investigates the efficacy of botulinum toxin in the management of adult onset focal dystonia in Great Britain. Etiology of focal dystonia; Site for the toxin injection for patients with blepharospasm; Discussion on other promising uses of the toxin.

  • Therapeutic uses of botulinum toxin. Whittlestone, Tim // GP: General Practitioner;3/20/2009, p36 

    The article offers information on the therapeutic uses of botulinum toxin medication for striated and smooth muscle spasm. The medication could be used for cosmetic purposes through electromyography which would the blockade of alphamotor neuron transmission can relax extra-ocular muscle. Another...

  • Botox improves patient-related outcomes in CD.  // PharmacoEconomics & Outcomes News;7/24/2010, Issue 608, p12 

    The article discusses research of the effectiveness of botulinum toxin A on treating pain in patients with cervical dystonia, referencing a study by M. Kurth and colleagues presented at the 14th International Congress of Parkinson's Disease and Movement Disorders."

  • Targeted Secretion Inhibitors--Innovative Protein Therapeutics. Keith, Foster; John, Chaddock // Toxins;Dec2010, Vol. 2 Issue 12, p2795 

    Botulinum neurotoxins are highly effective therapeutic products. Their therapeutic success results from highly specific and potent inhibition of neurotransmitter release with a duration of action measured in months. These same properties, however, make the botulinum neurotoxins the most potent...

  • Face-freezing toxin could stop diseases in their tracks.  // New Scientist;6/6/2009, Vol. 202 Issue 2711, p17 

    The article discusses a study on the potential of botulinum neurotoxin or botox as treatment for asthma and possibly even cancer, conducted by Joseph Barbieri and his colleagues at the Medical College of Wisconsin in Milwaukee. According to the researchers, Botox works by slicing up proteins...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics